Insider Trading Alert - ZLTQ, F And NTWK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 19, 2015, 59 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $38.95 to $5,000,001.05.

Highlighted Stocks Traded by Insiders:

ZELTIQ Aesthetics (ZLTQ) - FREE Research Report

Garcia Sergio, who is Senior VP, GC & Secretary at ZELTIQ Aesthetics, sold 10,000 shares at $30.00 on June 19, 2015. Following this transaction, the Senior VP, GC & Secretary owned 72,782 shares meaning that the stake was reduced by 12.08% with the 10,000-share transaction.

The shares most recently traded at $28.14, down $1.86, or 6.61% since the insider transaction. Historical insider transactions for ZELTIQ Aesthetics go as follows:

  • 4-Week # shares sold: 13,636
  • 12-Week # shares sold: 13,636
  • 24-Week # shares sold: 62,939

The average volume for ZELTIQ Aesthetics has been 548,000 shares per day over the past 30 days. ZELTIQ Aesthetics has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are up 1.9% year-to-date as of the close of trading on Thursday.

ZELTIQ Aesthetics, Inc., a medical technology company, engages in developing and commercializing non-invasive products for the selective reduction of fat. It offers CoolSculpting system, which utilizes proprietary controlled cooling technology to selectively reduce stubborn fat bulges. The company has a P/E ratio of 158.0. Currently, there are 5 analysts who rate ZELTIQ Aesthetics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ZLTQ - FREE

TheStreet Quant Ratings rates ZELTIQ Aesthetics as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the stock itself is trading at a premium valuation. Get the full ZELTIQ Aesthetics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

2 Small Biotechs Under $5 May Be Bargains

Small-Cap Turnaround Stories

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value